Vascular endothelial growth factor

Exonate announces the initiation of Phase Ib/II clinical trial for Diabetic Macular Oedema, as part of its collaboration with Janssen

Retrieved on: 
Tuesday, February 2, 2021
Branches of biology, Medical specialties, Organ systems, Angiology, Vascular endothelial growth factor, Diabetic retinopathy, Retinopathy, Retina, Neovascularization, Anti–vascular endothelial growth factor therapy, Vascular endothelial growth factor A

Dr Catherine Beech, Chief Executive Officer of Exonate, said: "The initiation of our first clinical trial is an important step in the validation of our eye drop approach.

Key Points: 
  • Dr Catherine Beech, Chief Executive Officer of Exonate, said: "The initiation of our first clinical trial is an important step in the validation of our eye drop approach.
  • The collaboration with Janssen has been incredibly positive and together, we have designed a study that we believe will deliver meaningful results."
  • By exploiting the alternative splicing of Vascular Endothelial Growth Factor (VEGF), Exonate has developed small-molecules for the treatment of retinal neovascular diseases.
  • Although DMO is more likely to occur as diabetic retinopathy worsens, it can happen at any stage of the disease.

Gemini Therapeutics Announces Initiation of GEM103 Phase 2a Study as an Add-On to Anti-VEGF Therapy for the Treatment of Wet AMD Patients at Risk for Progressive Vision Loss Due to Macular Atrophy

Retrieved on: 
Monday, February 1, 2021
Health, Genetics, Clinical trials, Pharmaceutical, Optical, Biotechnology, Branches of biology, Biology, Vascular endothelial growth factor, Macular degeneration, Angiology, Anti–vascular endothelial growth factor therapy, GEM103, Wet Age-Related Macular Degeneration (AMD), Gemini Therapeutics

Current anti-VEGF therapies have improved the quality of life for patients with wet AMD, said Marc E. Uknis, M.D., F.A.C.S., Chief Medical Officer of Gemini Therapeutics.

Key Points: 
  • Current anti-VEGF therapies have improved the quality of life for patients with wet AMD, said Marc E. Uknis, M.D., F.A.C.S., Chief Medical Officer of Gemini Therapeutics.
  • Wet AMD affects approximately 1.4 million people in the United States, and GEM103 is uniquely suited to correct CFH insufficiency associated with VEGF inhibition.
  • The clinical trial will be a randomized, single-masked, and sham-controlled study of patients requiring ongoing VEGF inhibition for wet AMD.
  • GEM103 is currently in a Phase 2a trial in dry AMD patients with a CFH risk variant.

EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of EYP-1901 for the Treatment of Wet AMD

Retrieved on: 
Thursday, January 28, 2021
Ophthalmology, Branches of biology, Organ systems, Blindness, Diabetes, Diabetic retinopathy, Vascular endothelial growth factor, Macular degeneration, Retinopathy, Anti–vascular endothelial growth factor therapy, Ranibizumab

In oral formulation, vorolanib demonstrated efficacy and ocular safety through Phase 2 trials in wet AMD.

Key Points: 
  • In oral formulation, vorolanib demonstrated efficacy and ocular safety through Phase 2 trials in wet AMD.
  • In addition to wet AMD, EYP-1901 is anticipated to be studied for the potential treatment of diabetic retinopathy and retinal vein occlusion in future clinical trials.
  • The Phase 1 DAVIO open-label, dose escalation trial, will examine thirteen wet AMD patients who were responsive to previous anti-VEGF treatments.
  • Based on clinical outcomes during the initial dose escalation phase, there is a potential to expand the trial.

OXURION to Participate in Upcoming Investor Meetings

Retrieved on: 
Thursday, January 7, 2021
Branches of biology, Clinical medicine, Medicine, Angiology, Anti–vascular endothelial growth factor therapy, Vascular endothelial growth factor, Euronext

THR-149 has shown positive topline Phase 1 results for the treatment of DME.

Key Points: 
  • THR-149 has shown positive topline Phase 1 results for the treatment of DME.
  • The Company is currently conducting a Phase 2 clinical trial evaluating multiple injections of THR-149 with DME-patients who previously responded sub-optimally to anti-VEGF therapy.
  • Oxurion is headquartered in Leuven, Belgium, and is listed on the Euronext Brussels exchange under the symbol OXUR.
  • This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction.

OXURION NV Confirms New Patents for THR-687 Issued by European and US Patent Offices

Retrieved on: 
Monday, November 9, 2020
Branches of biology, Medicine, Clinical medicine, Galapagos NV, Angiology, Euronext, Anti–vascular endothelial growth factor therapy, Vascular endothelial growth factor

THR-149 has shown positive topline Phase 1 results for the treatment of DME.

Key Points: 
  • THR-149 has shown positive topline Phase 1 results for the treatment of DME.
  • The Company is currently conducting a Phase 2 clinical trial evaluating THR-149 with DME-patients who previously responded sub-optimally to anti-VEGF therapy.
  • THR-687 is an optimized compound derived from a broader library of integrin inhibitors in-licensed from Galapagos NV (Euronext & NASDAQ: GLPG).
  • Oxurion is headquartered in Leuven, Belgium, and is listed on the Euronext Brussels exchange under the symbol OXUR.

Aerpio Pharmaceuticals to Report Third Quarter 2020 Financial Results on November 10

Retrieved on: 
Thursday, November 5, 2020
Branches of biology, Clinical medicine, Medicine, Hypoxia-inducible factors, Bispecific monoclonal antibody, Vascular endothelial growth factor, Macular degeneration, Intravitreal injection, Intravitreal administration

Recently published mouse and human genetic data implicate the Angpt/Tie2 pathway in maintenance of Schlemms canal, a critical component of the conventional outflow tract.

Key Points: 
  • Recently published mouse and human genetic data implicate the Angpt/Tie2 pathway in maintenance of Schlemms canal, a critical component of the conventional outflow tract.
  • The Companys third asset is a bispecific antibody that binds both VEGF and VE-PTP which is designed to inhibit VEGF activation and activate Tie2.
  • This bispecific antibody has the potential to be an improved treatment for wet age-related macular degeneration and DME via intravitreal injection.
  • Finally, the Company has exclusively out-licensed AKB-4924 (now called GB004), a first-in-class small molecule inhibitor of hypoxia-inducible factor-1 (HIF).

Basilea presents preclinical data on anti-angiogenic activity of derazantinib at ENA 2020

Retrieved on: 
Monday, October 26, 2020
Branches of biology, Tyrosine kinase receptors, Angiology, Medical specialties, Clusters of differentiation, Growth factors, Fibroblast growth factor receptor 1, Fibroblast growth factor receptor, Angiogenesis inhibitor, Vascular endothelial growth factor, Angiogenesis

In addition to FGFR1-3 derazantinib also inhibits the vascular endothelial growth factor receptor 2 (VEGFR2).

Key Points: 
  • In addition to FGFR1-3 derazantinib also inhibits the vascular endothelial growth factor receptor 2 (VEGFR2).
  • The presented data from several preclinical models demonstrate that derazantinib has an anti-angiogenic effect, which may contribute to its overall anti-tumor activity in FGFR-driven cancers.
  • Dr. Laurenz Kellenberger, Chief Scientific Officer, said: Our development strategy for derazantinib is focused on strengthening the evidence for its differentiation versus other FGFR inhibitors.
  • The preclinical data on derazantinibs anti-angiogenic activity presented at the conference show that it may provide additional activity on top of its established primary anti-tumor effects in FGFR-positive solid tumors.

UNC Researchers Identify Genetic Variant Linked to Drug-Induced Hypertension with Avastin®

Retrieved on: 
Thursday, October 22, 2020
Drugs, Branches of biology, Clinical medicine, Angiogenesis inhibitors, Bevacizumab, RTT, Vascular endothelial growth factor

The presentation can be viewed on Sunday, October 25th at 9:45 ET on the Conference website .

Key Points: 
  • The presentation can be viewed on Sunday, October 25th at 9:45 ET on the Conference website .
  • VEGF inhibitors like Avastin have revolutionized cancer treatment and have been used by millions of patients.
  • Dr. Federico Innocenti, Associate Professor at UNC who led the research added, "Early identification is a potential double win.
  • It will first help doctors identify patients at a higher risk of hypertension induced by Avastin.

Invitation OXURION R&D Investor Day – Virtual - 15 October 2020 at 5.30pm CET/ 11.30am ET

Retrieved on: 
Thursday, October 8, 2020
Health, Branches of biology, Medicine, Drug discovery, Clinical research, Clinical trial, Design of experiments, Pharmaceutical industry, Anti–vascular endothelial growth factor therapy, Vascular endothelial growth factor

THR-149 has shown positive topline Phase 1 results for the treatment of DME.

Key Points: 
  • THR-149 has shown positive topline Phase 1 results for the treatment of DME.
  • The Company is currently conducting a Phase 2 clinical trial evaluating THR-149 with DME-patients who previously responded sub-optimally to anti-VEGF therapy.
  • Positive topline results in a Phase 1 clinical study assessing it as a treatment for DME were announced in January 2020.
  • This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction.

Save The Date: Oxurion to host Virtual R&D Investor Day on 15 October 2020

Retrieved on: 
Monday, October 5, 2020
Health, Branches of biology, Medicine, Drug discovery, Clinical research, Clinical trial, Design of experiments, Pharmaceutical industry, Anti–vascular endothelial growth factor therapy, Vascular endothelial growth factor, Euronext

THR-149 has shown positive topline Phase 1 results for the treatment of DME.

Key Points: 
  • THR-149 has shown positive topline Phase 1 results for the treatment of DME.
  • The Company is currently conducting a Phase 2 clinical trial evaluating THR-149 with DME-patients who previously responded sub-optimally to anti-VEGF therapy.
  • Positive topline results in a Phase 1 clinical study assessing it as a treatment for DME were announced in January 2020.
  • Oxurion is headquartered in Leuven, Belgium, and is listed on the Euronext Brussels exchange under the symbol OXUR.